EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome



Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome



Pediatric Nephrology 20(9): 1265-1268



Most patients with minimal change nephrotic syndrome are steroid responsive and tolerate this medication. However, a substantial number of patients relapse frequently and become steroid dependent. These patients often require treatment with alternative immunosuppressive drugs to maintain remission and minimize steroid toxicity. Previous studies have suggested that mycophenolate mofetil is effective in treating these patients. However, there are limited data on the effectiveness of this agent in pediatric patients, specifically those with steroid-dependent nephrotic syndrome. The purpose of this study was to assess the efficacy and safety of mycophenolate mofetil therapy in children and adolescents with steroid-dependent nephrotic syndrome who failed other treatments. A retrospective chart review was performed on all patients with steroid-dependent nephrotic syndrome. Clinical characteristics, laboratory data and the relapse rate were assessed prior to and during mycophenolate mofetil treatment. Twenty-one patients, ages 2-17 years, with steroid-dependent nephrotic syndrome who were treated with mycophenolate mofetil between 2001-2005 were included in this review. The indication for mycophenolate mofetil use was steroid dependence in 17 and steroid toxicity in 4 patients. The mean duration of treatment was 1.0 +/- 0.5 years (range: 0.2-2.0 years). Patients treated with mycophenolate mofetil had a reduction in relapse rate from 0.80 +/- 0.41 to 0.47 +/- 0.43 relapses per month (P < 0.02). Side effects were mild and mostly gastrointestinal in nature. In 1 child, mycophenolate mofetil was discontinued due to varicella infection and not restarted. The findings indicate that mycophenolate mofetil is a useful adjunctive therapy in the treatment of patients with steroid-dependent nephrotic syndrome. It lowers the relapse rate by 40% and is well tolerated by patients with steroid-dependent nephrotic syndrome.

(PDF emailed within 0-6 h: $19.90)

Accession: 012026981

Download citation: RISBibTeXText

PMID: 15942779

DOI: 10.1007/s00467-005-1957-y



Related references

Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatric Nephrology 26(10): 1823-1828, 2011

Mycophenolate mofetil effectiveness in pediatric post-cyclophosphamide, steroid dependent nephrotic syndrome. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 109A, September, 2001

Use of mycophenolate mofetil as a cyclosporine sparing agent in pediatric patients with CSA dependent nephrotic syndrome. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 120A, September, 2001

Multicenter trial of mycophenolate mofetil in children with steroid dependent or frequent relapsing nephrotic syndrome Report of the Southwest Pediatric Nephrology Study Group. Journal of the American Society of Nephrology 14(Abstracts Issue): 751A, November, 2003

Mycophenolate mofetil allows steroid withdrawal in steroid dependent nephrotic syndrome. Pediatric Research 51(4 Part 2): 429A, April, 2002

Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatric Nephrology 18(8): 833-837, 2003

Mycophenolate mofetil in steroid-dependent idiopathic nephrotic syndrome. Pediatric Nephrology 31(11): 2095-2101, 2016

Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome. Nephrology 21(1): 21-27, 2016

Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatric Nephrology 20(7): 914-919, 2005

Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatric Nephrology 22(12): 2059-2065, 2007

Mycophenolate mofetil in treatment of childhood steroid-dependent nephrotic syndrome. La Tunisie Medicale 94(3): 221-225, 2016

Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. American Journal of Kidney Diseases 42(6): 1114-1120, 2003

Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. Pediatric Nephrology 27(3): 389-396, 2012

Outcome of severe steroid-dependent nephrotic syndrome treated with mycophenolate mofetil. Pediatric Nephrology 28(1): 93-97, 2013

Treatment of steroid-dependent minimal change-nephrotic syndrome with mycophenolate mofetil. Nefrologia 24(1): 79-82, 2004